Physician profile
Lev Goldiner
NPI 1710146733
$221,291.02
in general payments reported to CMS, 2019-2025
74 companies · $20K in 2025
The $20K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $32K · 2021: $49K · 2022: $39K · 2023: $31K · 2024: $16K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Food and Beverage: $18K · Consulting Fee: $3,925 · Education: $250 · Travel and Lodging: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,200.50 |
| Food and Beverage | $17,505.84 |
| Consulting Fee | $3,925.00 |
| Education | $250.44 |
| Travel and Lodging | $226.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $58,691.56 | 2021-2025 | |
| Emd Serono, INC. | $45,328.06 | 2019-2025 | Mavenclad, Mavenclad |
| Genzyme Corporation | $24,476.90 | 2019-2025 | |
| Allergan, INC. | $22,218.51 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $19,594.04 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $14,064.90 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $7,111.70 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $5,744.06 | 2022 | |
| Avanir Pharmaceuticals, INC. | $5,344.55 | 2019-2022 | |
| Ucb, INC. | $1,617.58 | 2021-2025 | Briviact, Rystiggo, Nayzilam |
| Sk Life Science, INC. | $1,232.24 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $1,131.02 | 2019-2025 | Ultomiris, Koselugo |
| Novartis Pharmaceuticals Corporation | $1,090.89 | 2019-2025 | |
| Lilly USA, LLC | $1,023.65 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Celgene Corporation | $851.48 | 2020-2025 | Zeposia |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lev Goldiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.